Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site. # Peptilogics Custom Engineered with Intention. ## Sitemaps - [XML Sitemap](https://peptilogics.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections](https://peptilogics.com/news/peptilogics-begins-pivotal-trial-of-first-ever-drug-designed-to-cure-medical-device-related-infections/) - [Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial](https://peptilogics.com/news/peptilogics-raises-78-million-to-advance-zaloganan-into-pivotal-trial/) - [Peptilogics Reports Positive 180-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)](https://peptilogics.com/news/peptilogics-reports-positive-180-day-top-line-interim-data-from-phase-1b-trial-of-plg0206-in-patients-with-periprosthetic-joint-infection-pji/) - [Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)](https://peptilogics.com/news/peptilogics-reports-positive-90-day-top-line-interim-data-from-phase-1b-trial-of-plg0206-in-patients-with-periprosthetic-joint-infection-pji/) - [Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023](https://peptilogics.com/news/peptilogics-completes-phase-1b-trial-enrollment-and-will-present-interim-top-line-safety-and-tolerability-data-of-plg0206-in-patients-undergoing-dair-for-the-treatment-of-periprosthetic-joint-infectio/) - [Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)](https://peptilogics.com/news/peptilogics-hosting-panel-discussion-with-leading-industry-experts-on-the-high-unmet-medical-need-and-opportunity-in-periprosthetic-joint-infections-pji/) - [Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection](https://peptilogics.com/news/peptilogics-to-present-data-at-idweek-2022/) - [Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance](https://peptilogics.com/news/peptilogics-presents-data-demonstrating-antimicrobial-activity-against-difficult-to-treat-bacterial-pathogens/) - [Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection](https://peptilogics.com/news/peptilogics-announces-first-patient-dosed-in-phase-1b-study-of-plg0206-for-periprosthetic-joint-infection/) - [Epiaxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership](https://peptilogics.com/news/epiaxis-therapeutics-peptilogics-enter-strategic-drug-discovery-partnership/) - [Peptilogics Strengthens Leadership Team with Executive Appointments](https://peptilogics.com/news/peptilogics-strengthens-leadership-team-with-executive-appointments/) - [Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh](https://peptilogics.com/news/peptilogics-to-participate-in-musculoskeletal-infection-society-msis-32nd-annual-open-scientific-meeting-in-pittsburgh/) - [Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022](https://peptilogics.com/news/peptilogics-to-present-data-highlighting-designed-antimicrobial-peptide-for-the-treatment-of-periprosthetic-joint-infection-pji-at-eccmid-2022/) - [Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection](https://peptilogics.com/news/peptilogics-receives-fda-fast-track-designation-for-plg0206-an-investigational-peptide-therapeutic-in-development-for-the-treatment-of-periprosthetic-joint-infection/) - [Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target](https://peptilogics.com/news/orion-biotechnology-and-peptilogics-enter-strategic-research-collaboration-to-enable-ai-driven-drug-discovery-against-undrugged-gpcr-target/) - [Peptilogics Promotes Nicholas Nystrom, Ph.D., to Chief Technology Officer](https://peptilogics.com/news/peptilogics-promotes-nicholas-nystrom-ph-d-to-chief-technology-officer/) - [Peptilogics Strengthens Leadership Team with Three Strategic Appointments](https://peptilogics.com/news/2021/peptilogics-strengthens-leadership-team-with-three-strategic-appointments/) - [Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy](https://peptilogics.com/news/2021/peptilogics-announces-successful-completion-of-phase-1-clinical-trial-of-plg0206-a-first-in-class-anti-infective-peptide-therapy/) - [Peptilogics Strengthens Leadership Team with Five Key Strategic Hires](https://peptilogics.com/news/2021/peptilogics-strengthens-leadership-team-with-five-key-strategic-hires/) - [Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics](https://peptilogics.com/news/2021/peptilogics-and-cerebras-systems-partner-on-ai-solutions-to-advance-the-future-of-peptide-therapeutics/) - [Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021](https://peptilogics.com/news/2021/peptilogics-to-present-first-in-human-phase-1-clinical-data-of-plg0206-at-idweek-2021/) - [Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021](https://peptilogics.com/news/2021/peptilogics-presents-positive-first-in-human-phase-1-data-for-its-lead-engineered-antibacterial-peptide-plg0206-at-idweek-2021/) - [Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection](https://peptilogics.com/news/peptilogics-announces-fda-clearance-of-investigational-new-drug-application-to-initiate-clinical-trial-of-plg0206-in-periprosthetic-joint-infection/) - [Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection](https://peptilogics.com/news/2021/peptilogics-announces-two-peer-reviewed-publications-on-designed-peptide-therapeutic-plg0206-for-periprosthetic-joint-infection/) - [Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)](https://peptilogics.com/news/peptilogics-presentations-at-american-academy-of-orthopedic-surgeons-aaos-2022-annual-meeting-highlight-peptide-therapeutic-plg0206-for-the-treatment-of-periprosthetic-joint-infection-pji/) - [Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis](https://peptilogics.com/news/peptilogics-receives-award-from-the-cystic-fibrosis-foundation-to-investigate-plg0301-and-plg0206-as-potential-dual-acting-treatments-for-lung-infections-associated-with-cystic-fibrosis/) - [Chief Financial Officer](https://peptilogics.com/careers/chief-financial-officer-2/) - [Summer 2022 Internship – AI & Data Science](https://peptilogics.com/careers/chief-financial-officer/) ## Pages - [Home](https://peptilogics.com/) - [Patients](https://peptilogics.com/patients/) - [Pipeline](https://peptilogics.com/pipeline/) - [Company](https://peptilogics.com/company/) - [News](https://peptilogics.com/news/) - [Contact](https://peptilogics.com/contact/) - [AI Discovery Platform](https://peptilogics.com/ai-discovery-platform/) - [Careers](https://peptilogics.com/careers/) - [Terms of Use](https://peptilogics.com/terms-of-use/) - [Privacy Policy](https://peptilogics.com/privacy-policy/) - [Footer](https://peptilogics.com/footer/) ## Portfolio Items - [Ian Friedland, MD](https://peptilogics.com/our-team/ian-friedland-md/) - [Albert Fonticiella MBA, SHRM-SCP](https://peptilogics.com/our-team/albert-fonticiella/) - [Ellie Hershberger, PharmD](https://peptilogics.com/our-team/ellie-hershberger-pharmd/) - [Nicholas Nystrom, PhD](https://peptilogics.com/our-team/nicholas-nystrom-phd/) - [Nick Pachuda, DPM](https://peptilogics.com/our-team/nick-pachuda-dpm/) - [Jonathan Steckbeck, PhD, MBA](https://peptilogics.com/our-team/jonathan-steckbeck-phd-mba/) ## Categories - [2021](https://peptilogics.com/category/news/2021/) - [news](https://peptilogics.com/category/news/) - [careers](https://peptilogics.com/category/careers/) - [2022](https://peptilogics.com/category/news/2022/) - [2023](https://peptilogics.com/category/news/2023/) - [2025](https://peptilogics.com/category/news/2025/) - [2026](https://peptilogics.com/category/news/2026/) ## Portfolio Categories - [Team](https://peptilogics.com/portfolio_entries/team/) - [corporate](https://peptilogics.com/portfolio_entries/corporate/) - [technology](https://peptilogics.com/portfolio_entries/technology/) - [drug development](https://peptilogics.com/portfolio_entries/drug-development/)